Trintellix, Brintellix(vortioxetine)
Brintellix, Trintellix (vortioxetine) is a small molecule pharmaceutical. Vortioxetine was first approved as Trintellix on 2013-09-30. It is used to treat major depressive disorder in the USA. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B, sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 1A. In addition, it is known to target 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Trintellix (discontinued: Trintellix, Vortioxetine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trintellix | New Drug Application | 2025-04-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| major depressive disorder | EFO_0003761 | D003865 | F22 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VORTIOXETINE HYDROBROMIDE, TRINTELLIX, TAKEDA PHARMS USA | |||
| 2024-01-22 | M-187 | ||
| 2023-11-13 | M-267 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Vortioxetine Hydrobromide, Trintellix, Takeda Pharms Usa | |||
| 9278096 | 2032-03-21 | U-2436 | |
| 8722684 | 2031-06-30 | DS, DP | |
| 8969355 | 2027-06-15 | U-1668 | |
| 9125908 | 2027-06-15 | U-2309 | |
| 9125909 | 2027-06-15 | U-2309 | |
| 9125910 | 2027-06-15 | U-2309 | |
| 9227946 | 2027-06-15 | U-1668 | |
| 9861630 | 2027-06-15 | U-1668 | |
| 11458134 | 2027-06-15 | DP | U-3463 |
| 7144884 | 2026-06-17 | DS, DP | U-1439 |
HCPCS
No data
Clinical
Clinical Trials
110 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 6 | 13 | 34 | 17 | 8 | 75 |
| Depression | D003863 | — | F33.9 | 3 | 13 | 35 | 19 | 3 | 69 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 4 | 9 | 33 | 15 | 9 | 68 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | 2 | 3 | 3 | — | 9 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 2 | 6 | 2 | — | 9 |
| Healthy volunteers/patients | — | — | — | 4 | — | — | 1 | — | 5 |
| Recurrence | D012008 | — | — | — | — | 2 | 1 | — | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | 1 | 1 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 2 | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 2 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Generalized anxiety disorder | D000098647 | — | — | — | — | 5 | — | — | 5 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 2 | 2 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 2 |
| Treatment outcome | D016896 | — | — | — | — | 1 | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
| Radiation injuries | D011832 | — | T66 | — | — | 1 | — | — | 1 |
| Hoarding disorder | D000067836 | — | F42.3 | — | — | 1 | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | 1 | — | — | 1 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bulimia | D002032 | — | F50.2 | — | 1 | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | — | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 1 | — | — | — | 1 |
| Hyperkinesis | D006948 | — | — | — | 1 | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | 1 | — | — | — | 1 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognition disorders | D003072 | — | — | 1 | — | — | — | — | 1 |
| Coronary disease | D003327 | — | — | 1 | — | — | — | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Magnetic resonance imaging | D008279 | — | — | — | — | — | — | 1 | 1 |
| Electroconvulsive therapy | D004565 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vortioxetine |
| INN | vortioxetine |
| Description | Vortioxetine is an N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. It has a role as an antidepressant, an anxiolytic drug, a serotonergic agonist and a serotonergic antagonist. It is a N-arylpiperazine and an aryl sulfide. It is a conjugate base of a vortioxetine(1+). |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type): thioether derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 508233-74-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2104993 |
| ChEBI ID | 76016 |
| PubChem CID | 9966051 |
| DrugBank | DB09068 |
| UNII ID | 3O2K1S3WQV (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1B
HTR1B
SLC6A4
SLC6A4
HTR7
HTR7
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Alternate
HTR5A
HTR5A
HTR6
HTR6
HTR2A
HTR2A
HTR1D
HTR1D
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Trintellix – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Vortioxetine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,835 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trintellix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,988 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use